Drug Metabolism/Pharmacology

Top Story

FDA grants orphan drug designation for primary hyperoxaluria treatment

July 14, 2017

Allena Pharmaceuticals has received an orphan drug designation from the FDA for its investigational product ALLN-177 for the treatment of primary hyperoxaluria and markedly elevated urinary oxalate excretion, according a press release.

“This is an important regulatory designation to advance the development of ALLN-177 for patients who could benefit from novel therapeutic options that directly address excess oxalate,” Louis Brenner, MD, president and COO of Allena Pharmaceuticals, said in the press release. “We are committed to the development of ALLN-177 for the treatment of patients with severe hyperoxaluria disorders.”

In the Journals

Legal marijuana use linked to more dependency, persistent vomiting

July 13, 2017
Chronic use of cannabinoid derivatives led to a significant increase in cannabinoid hyperemesis syndrome, characterized by episodes of severe nausea and cyclical…

FDA approves Vantrela ER for severe pain

January 18, 2017
The FDA has approved Vantrela ER, an extended release tablet, for patients with severe pain that necessitates long-term, around-the-clock treatment, according to a press…
In the Journals

Combatting antimicrobial resistance critical for patients with cirrhosis

September 1, 2016
Worldwide public health concerns over antimicrobial resistance in pathogenic bacteria make it important to find solutions for preventing the spread of resistant…
More Headlines »
CME

The Evolution of SOC in HCV: What Have We Learned About Starting Therapy Today?

This activity is supported by an educational grant from Genentech.

The biggest surprises that I have encountered in treating patients after the approval of telaprevir and boceprevir in…
More »
GI Bookshelf

Chapter 5: The Malabsorption Syndrome

From Clinical Nutrition in Gastrointestinal Disease
More »
Resource Centers
International Liver Congress

International Liver Congress

Video
Meeting News Coverage

Sofosbuvir, ribavirin therapy after liver transplant shows positive results for HCV patients

November 15, 2013
More »
Advertisement
Advertisement